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Table 1
Results Summary
Baseline (3 months) Follow-up (2 years)
APM Control APM Control
Medial Tibial Cartilage Volume
(mm3)
1934384 NA 1864369* NA
Gait Speed (m/sec) 1.880.3 1.970.2 1.900.2 1.930.2
Medial Knee Load:
Peak KAM(Nm/BW*ht%) 2.81.2a 2.51.1 3.21.2* 2.61.3
Peak KAM Impulse(Nm.s/BW*ht%) 0.80.3a 0.60.3 0.80.3b 0.60.3
Isokinetic Strength @ 60/sec (Nm/kg):
Concentric Quadriceps 1.720.5a 2.060.4 1.940.4* 2.040.5
Eccentric Quadriceps 2.220.7a 2.610.7 2.420.7* 2.440.7
Concentric Hamstrings 0.960.3a 1.110.3 1.090.3* 1.150.3
Eccentric Hamstrings 1.370.4a 1.610.3 1.480.4* 1.500.4
ap<0.05 compared to control at baseline; bp<0.05 compared to control at follow-up;
*p<0.5 compared to APM at baseline; NA¼not assessed
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However, the role of Sdc4 in embryonic and adult bone formation has
not been elucidated. To investigate the role of Sdc4 in these processes,
we used Sdc4-/- mice to analyze the distribution and functional role of
Scd4 in endochondral ossiﬁcation of mouse embryos and in adult
fracture repair, which recapitulates endochondral ossiﬁcation, but like
osteoarthritis involves an inﬂammatory component.
Methods: Sdc4 promoter activity was anlysed in Sdc4-/-/LacZ knock-in
animals, using b-galactosidase stainings. E16.5 embyros were used for
histological (alcian blue/alizarin red) and immunohistological (PCNA,
Col10a1, ADAMTS-4, BC-3, Sdc2) stainings and the calciﬁed bone area
was quantiﬁed using whole mount stainings of these embryos. Histo-
logical (Masson-Goldner, alcian blue) and immunohistological (Col10a1,
Sdc2, PCNA) stainings at day 7, 14 and 28 fracture calli were performed.
Callus size and cartilage area were quantiﬁed using image J. Chon-
drocytes were isolated from neonatal knee joints and embyronal
cartilage. Proliferation was investigated using MTT assay. Gene
expression analysis for Sdc-2, Sdc-4 with and without stimulation using
TNFa and WNT3a was performed using quantitative RT-PCR.
Results: Sdc4 promoter activity was detectable in all stages of chon-
drocyte differentiation, and Sdc4 deﬁciency inhibited chondrocyte
proliferation both in vivo and in vitro. Moreover, aggrecan turn over in
the epiphysial cartilage was decreased transiently in vivo, but this did
not lead to a growth phenotype at birth. In contrast, fracture healing in
adult mice was markedly delayed in Sdc4-/- animals and accompanied
by increased callus formation. Analysing the discrepancy between the
mild embryonic and the severe adult phenotype, we found a compen-
satory up-regulation of Sdc2 in the developing cartilage of sdc4-/- mice
that was absent in adult tissue. Stimulation of chondrocytes withWnt3a
in vitro, led to an increased expression of Sdc2, while stimulation with
TNFa resulted in an up-regulation of Sdc4 but a decreased expression of
Sdc2.
Conclusions:We conclude that Sdc4 is functionally involved in endo-
chondral ossiﬁcation and that the loss of Sdc4 impairs adult fracture
healing due to the inhibition of compensatory mechanisms under
inﬂammatory conditions.
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ARTHROSCOPIC PARTIAL MEDIAL MENISCECTOMY IS ASSOCIATED
WITH HIGHER MEDIAL KNEE JOINT LOAD AND REDUCTIONS IN
MEDIAL ARTICULAR CARTILAGE VOLUME DESPITE TYPICAL KNEE
STRENGTH AT 2 YEARS POST-SURGERY
K.L. Bennell 1, T.V. Wrigley 1, F.M. Cicuttini 2, B.R. Metcalf 1, M. Hall 1,
A.R. Dempsey 3, P.M. Mills 3, R.S. Hinman 1, Y. Wang 2, D.G. Lloyd 3. 1 The
Univ. of Melbourne, Melbourne, Australia; 2Monash Univ., Melbourne,
Australia; 3Grifﬁth Univ., Queensland, Australia
Purpose: Arthroscopic partial meniscectomy (APM) is one of the most
common orthopaedic surgeries performed. Following APM, individuals
are considered to be at a higher risk to develop early-onset knee oste-
oarthritis (OA). A higher external knee adduction moment (KAM) and
reduced knee extensor strength have been described in persons with
recent APM surgery. It is speculated that impaired knee muscle strength
contributes to higher KAM in this cohort. The purpose of this study was
to compare gait, knee strength and medial tibial cartilage volume
between: a) individuals 3 months post-APM surgery and a comparable
healthy control group, b) individuals 2 years post-APM surgery and
a comparable healthy group, c)individuals 3 months post-APM surgery
(baseline) and 2 years post-APM surgery (follow-up). Speciﬁcally,
independent variables included: 1) peak KAM, 2) KAM impulse, 3)
isokinetic knee extensor and ﬂexor strength and, 4) medial tibial
articular cartilage volume.
Methods: Eighty-two participants with APM were assessed at baseline
(88% male; age 415yrs; BMI 27.3 4.0kg/m2) and 65 (79%) returned
at follow-up (86% male; age 416yrs; BMI 27.34.6kg/m2).Thirty-
eight healthy controls were assessed at baseline (84% male; age
417yrs; BMI 25.03.4kg/m2) and 23 (61%) returned at follow-up
(87% male; age 427yrs; BMI 25.53.4kg/m2). Gait (8-camera VICON,
3 AMTI force plates) and isokinetic knee muscle strength (KinCom
dynamometer) were assessed at baseline and follow-up in both
groups. Participants walked barefoot at their self-selected fast pace,
and the ﬁrst peak KAM and KAM impulse were calculated during
stance using inverse dynamics and averaged over ﬁve trials. Partici-
pants performed ﬁve maximal isokinetic quadriceps and hamstring
contractions with highest score recorded. Medial tibial cartilagevolume was determined from MRI in the APM cohort at baseline and
at follow-up. Between group differences were determined using
ANCOVA (gait parameters with gait speed included as covariate) and
ANOVA (strength) at each time-point. Paired t-tests determined
differences between within the APM group over time. Signiﬁcance was
set at p<0.05.
Results: In addition to differences between the APM and control group
at baseline and follow-up, differences were also observed within the
APM group over time (Table 1). In the APM group, peak KAM and KAM
impulse were signiﬁcantly elevated at 3 months, and KAM impulse was
signiﬁcantly higher at 2 years post-surgery compared to controls.
Furthermore, peak KAM increased over time (by 14%) from baseline to
follow-up in the APM group. At baseline, isokinetic quadriceps and
hamstring strength was signiﬁcantly weaker in the APM group as
compared to controls. However at follow-up, no differences in quadri-
ceps or hamstring strength existed between groups. For the APM group,
medial tibial cartilage volume was signiﬁcantly reduced by 3.5% over
time.
Conclusions: Our ﬁndings suggest that greater medial knee joint
loading compared to controls was present 3 months post-APM surgery
and it remained elevated 2 years later, despite recovery of weaker knee
muscle strength to control levels. Further, there was a reduction in
medial tibial cartilage volume in the APM cohort over this time. It is
possible that elevatedmedial knee joint loading contributed to cartilage
volume loss. Alternative neuromuscular factors to strength, or other
contributors, may be responsible for KAM parameters remaining higher
at 2 years post-surgery.33
EFFECTIVE KNOCK DOWN OF MMP13 BY INTRA-ARTICULAR
INJECTION OF SMALL INTERFERING RNA (SIRNA) IN MURINE
SURGICALLY INDUCED OSTEOARTHRITIS MODEL
R. Akagi 1, T. Sasho 1, M. Saito 1, N. Ikegawa 1, S. Mukoyama 1,
Y. Muramatsu 1, S. Yamaguchi 1, K. Nakagawa 2, K. Takahashi 1. 1Chiba
Univ. Hosp., Chiba, Japan; 2 Sakura Med. Ctr. Toho Univ. Hosp., Chiba, Japan
Purpose: In the pathogenesis of osteoarthritis (OA), several
proteases including the MMP (matrix metalloproteinase) family
and ADAMTS (a disintegrin and metalloprotease with thrombo-
spondin motifs) family are thought to play a part in the early phase
of cartilage degradation. Among them, MMP13 is presumed to be
one of the major players, and inhibition of this protease has been
demonstrated to prevent cartilage degradation in animal osteoar-
thritic models. However, there is no conﬁrmed effective method to
safely achieve suppression of these enzymes postnatally in vivo.
The RNA interference (RNAi) technique using small interfering
RNAs (siRNAs) has been proven to be beneﬁcial in knocking down
protease effects in vitro, but there are still unsolved problems
before applying this method in vivo, due to the molecular insta-
bility and difﬁculty in transfecting siRNAs in vivo. Recently,
chemically modulated siRNAs which do not require transfection
agents or other additional techniques such as electroporation in
transfecting into cells have been developed. These siRNAs can be
applied simply to cells with low cellular toxicity, and is likely to be
suitable for in vivo use.
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cartilage degradation by directly injecting chemically modulated siR-
NAs to surgically induced murine OA knee joints. Our hypothesis was
that effective RNAi could be achieved by injection of highly concen-
trated siRNA in the knee joint, resulting in reduced development of
osteoarthritis.
Methods: Knee OAs were surgically induced to C57BL/6 mice by
destabilization of the medial meniscus (DMM) method, by trans-
ecting the medial meniscotibial ligament under general anesthesia.
To determine the timing of protease expressions in the murine DMM
induced OA model, messenger RNA (mRNA) of MMP13 from knee
cartilage were analyzed at 3 days, 1 week, 2 weeks, 4 weeks, and 6
weeks after surgery by quantitative polymerase chain reaction
(qPCR).
One week after DMM induction, chemically modulated siRNAs were
injected in the knee joint. Two different content of injection were
evaluated. Treatment groups consisted of a group which MMP13 siRNA
was injected, and another group in which control siRNA was injected.
The control siRNAwas conﬁrmed not to affect MMP13 in vitro. The RNAi
effects were assessed by quantifying MMP13 mRNA in knee cartilage at
48 hours after siRNA injection. Histological assessment of articular
cartilage at 8 weeks post DMM operation was conducted to assess the
effect of siRNA injection at one week after DMM in osteoarthritis
progression, according to the OARSI recommendation for OA knee
scoring in mice.
Results: Surgically induced OAs were successfully achieved in
the DMM model of mice. MMP13 expressions elevated from the
third post operative day, and peaked in a week after DMM surgery
(Fig. 1). Expression level of MMP13 mRNA was signiﬁcantly
decreased at 48 hours after injection of MMP13 siRNA to the knee
joint, compared to negative control siRNA injection (Fig. 2).
Signiﬁcant improvement was observed in the histological score of
MMP siRNA treated group, compared to the control siRNA injected
group.
Conclusions: Direct injection of siRNAs targeting MMP13 at the early
phase of OA development has the potential to inhibit protease expres-
sion and inhibits cartilage degradation in vivo.ĂĂ34
FIVE TO TEN YEAR FOLLOW UP OF MATRIX ASSOCIATED
AUTOLOGOUS CHONDROCYTE TRANSPLANTATION (MACT) IN THE
KNEE
M. Brix 1, C. Chiari 1, S. Nehrer 2, R. Windhager 1, S. Domayer 1. 1Med.
Univ. of Vienna, Vienna, Austria; 2Danube Univ. Krems, Krems, Austria
Purpose: Compared to the original autologous cartilage transplantation
technique, matrix associated autologous cartilage transplantation
(MACT) techniques, as a possibility of cartilage repair technique, have
achieved comparable outcome at mid-term, but there is still a lack of
long-term results. The goal of this study was to obtain ﬁrst results after
10 years in a MACT technique in the knee.
Methods: A total number of 53 (22 female, 31 male) patients with
articular cartilage lesions of the knee were included in this prospective
case series. The average age ( SD) at implantation was 32  12 years
and the average Body Mass Index (BMI) was 24.5  3.8 kg/m2. The
average defect size was 4.4  1.9 cm2 (50 single defects, 3 patients with
multiple defects). All defects were classiﬁed as Outerbridge III or IV.
Primary indications (42 patients) were a stable joint, normal knee
alignment, isolated chondral defects with otherwise healthy adjacent
cartilage and age < 55 years. Secondary indications (11 patients) were
not fulﬁlling the primary indication criteria or were salvage procedures.
Four clinical scores (subjective IKDC knee form, Lysholm score, the
patient perception scale of the Cincinnati knee rating system, objective
IKDC knee form) were obtained for clinical evaluation. All patients were
treated with Hyalograft C.
Results: Altogether, 3 of 53 patients reached the 10-year follow up to
this day. In this study group, we depicted a signiﬁcant increase in the
Cincinnati patient perception scale when compared to pre surgery
scores(2.9 vs. 8.0; p<0.01). The 8-year follow up group showed
signiﬁcant differences in the Lysholm score (57.4 vs. 83.4; p<0.01), the
IKDC subjective score (49.3 vs. 67.8; p<0.05) and the Cincinnati
patient perception scale (2.1 vs. 7.4; p<0.01). Graft failure occurred in
3 of 42 patients with primary indications and 9 of 11 patients with
secondary indications. The difference was statistically signiﬁcant
(p<0.001).
Conclusions: Our data suggests, that the promising short-term results
were also found at mid- and long-term in younger patients (< 40 years)
with stable joints, normal knee alignment and single defects. In
contrast, salvage cases did not proﬁt from the treatment.
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A PHASE IIA CLINICAL STUDY OF TISSUEGENE-C (TG-C) IN PATIENTS
WITH OSTEOARTHRITIS
C.-W.Ha 1, S.H. Park 2, J.J. Cho 2, T.W. Kim2,M.J. Noh 3,M.C. Lee 4. 1 Samsung
Med. Ctr., Seoul, Republic of Korea; 2Kolon Life Sci., GwaChun, Republic of
Korea; 3 TissueGene, Inc, Rockville, MD, USA; 4 Seoul Natl. Univ. Hosp.,
Seoul, Republic of Korea
Purpose: TG-C is a gene and cell therapy for osteoarthritis that employs
ex vivo gene delivery via a retrovirally transduced, established line of
chondrocytes that overexpress transforming growth factor-b1 (TGF-b1).
TG-C contains normal (hChonJ) and transduced (hChonJb#7) chon-
drocytes by the ratio of 3:1. The hChonJ cells are normal allogeneic
chondrocytes and the hChonJb#7 cells are chondrocytes transduced
with TGF-b1 gene-containing retroviral vector, and further treated with
gamma-ray irradiation to limit their survival for up to 2 weeks in
patients. The gamma-ray irradiation was designed to render them
incapable of cell division and therefore to eliminate any possibility of
these cells causing cancer. Phase I study has demonstrated that no
severe adverse events (SAEs) were observed and dose limiting toxicity
was not observed up to the dose level of 3x107 cells/knee.
Methods: In the current study, the randomized and single blind phase
IIa trials were conducted to determine both safety and efﬁcacy in
patients with knee osteoarthritis. Participants (n ¼ 27, 21 females and
6 males) with a conﬁrmed diagnosis of knee osteoarthritis by MRI
were randomized to either 0.6x107 cells/knee (low dose group, n ¼ 13,
mean age of 60.467.50 year) or 1.8x107 cells/knee (high dose group,
n ¼ 14, mean age of 58.29  6.94 year) of TG-C treatment. The
primary evaluation was International Knee Document Committee
(IKDC) which is comprised of three sub-scales: pain, sports activities,
and daily function. The secondary evaluations were Western-Ontario
and MacMaster University (WOMAC) score and 100 mm Visual
Analogue Scale (VAS). These parameters were evaluated at 12, 24 and
